vs

Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and SHOE CARNIVAL INC (SCVL). Click either name above to swap in a different company.

SHOE CARNIVAL INC is the larger business by last-quarter revenue ($297.2M vs $154.2M, roughly 1.9× BridgeBio Pharma, Inc.). SHOE CARNIVAL INC runs the higher net margin — 4.9% vs -126.2%, a 131.2% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs -3.2%). SHOE CARNIVAL INC produced more free cash flow last quarter ($19.7M vs $-56.5M).

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...

Shoe Carnival Inc. is an American retailer of family footwear. The company operates 429 stores throughout the midwest, south, and southeast regions, and Puerto Rico. It was founded by David Russell in 1978 and is headquartered in Fort Mill, South Carolina as of 2025.

BBIO vs SCVL — Head-to-Head

Bigger by revenue
SCVL
SCVL
1.9× larger
SCVL
$297.2M
$154.2M
BBIO
Growing faster (revenue YoY)
BBIO
BBIO
+2524.4% gap
BBIO
2521.2%
-3.2%
SCVL
Higher net margin
SCVL
SCVL
131.2% more per $
SCVL
4.9%
-126.2%
BBIO
More free cash flow
SCVL
SCVL
$76.2M more FCF
SCVL
$19.7M
$-56.5M
BBIO

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
BBIO
BBIO
SCVL
SCVL
Revenue
$154.2M
$297.2M
Net Profit
$-194.6M
$14.6M
Gross Margin
94.7%
37.6%
Operating Margin
-90.5%
6.3%
Net Margin
-126.2%
4.9%
Revenue YoY
2521.2%
-3.2%
Net Profit YoY
27.2%
-23.9%
EPS (diluted)
$-1.00
$0.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBIO
BBIO
SCVL
SCVL
Q4 25
$154.2M
$297.2M
Q3 25
$120.7M
$306.4M
Q2 25
$110.6M
$277.7M
Q1 25
$116.6M
$262.9M
Q4 24
$306.9M
Q3 24
$332.7M
Q2 24
$300.4M
Q1 24
$211.1M
$280.2M
Net Profit
BBIO
BBIO
SCVL
SCVL
Q4 25
$-194.6M
$14.6M
Q3 25
$-184.9M
$19.2M
Q2 25
$-183.8M
$9.3M
Q1 25
$-169.6M
$14.7M
Q4 24
$19.2M
Q3 24
$22.6M
Q2 24
$17.3M
Q1 24
$-36.2M
$15.5M
Gross Margin
BBIO
BBIO
SCVL
SCVL
Q4 25
94.7%
37.6%
Q3 25
94.6%
38.8%
Q2 25
96.7%
34.5%
Q1 25
97.7%
34.9%
Q4 24
36.0%
Q3 24
36.1%
Q2 24
35.6%
Q1 24
99.7%
35.6%
Operating Margin
BBIO
BBIO
SCVL
SCVL
Q4 25
-90.5%
6.3%
Q3 25
-120.3%
8.2%
Q2 25
-121.4%
4.3%
Q1 25
-89.5%
5.3%
Q4 24
8.0%
Q3 24
9.0%
Q2 24
7.5%
Q1 24
0.2%
7.1%
Net Margin
BBIO
BBIO
SCVL
SCVL
Q4 25
-126.2%
4.9%
Q3 25
-153.2%
6.3%
Q2 25
-166.2%
3.4%
Q1 25
-145.4%
5.6%
Q4 24
6.3%
Q3 24
6.8%
Q2 24
5.8%
Q1 24
-17.1%
5.5%
EPS (diluted)
BBIO
BBIO
SCVL
SCVL
Q4 25
$-1.00
$0.53
Q3 25
$-0.95
$0.70
Q2 25
$-0.95
$0.34
Q1 25
$-0.88
$0.53
Q4 24
$0.70
Q3 24
$0.82
Q2 24
$0.63
Q1 24
$-0.20
$0.57

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBIO
BBIO
SCVL
SCVL
Cash + ST InvestmentsLiquidity on hand
$570.1M
$107.7M
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$-2.1B
$683.2M
Total Assets
$936.0M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBIO
BBIO
SCVL
SCVL
Q4 25
$570.1M
$107.7M
Q3 25
$643.0M
$91.9M
Q2 25
$756.9M
$93.0M
Q1 25
$540.6M
$123.1M
Q4 24
$91.1M
Q3 24
$84.5M
Q2 24
$69.5M
Q1 24
$519.7M
$111.2M
Total Debt
BBIO
BBIO
SCVL
SCVL
Q4 25
$2.0B
Q3 25
$2.0B
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BBIO
BBIO
SCVL
SCVL
Q4 25
$-2.1B
$683.2M
Q3 25
$-1.9B
$670.7M
Q2 25
$-1.8B
$653.6M
Q1 25
$-1.6B
$649.0M
Q4 24
$635.7M
Q3 24
$618.5M
Q2 24
$597.8M
Q1 24
$-1.0B
$583.4M
Total Assets
BBIO
BBIO
SCVL
SCVL
Q4 25
$936.0M
$1.2B
Q3 25
$998.3M
$1.2B
Q2 25
$1.1B
$1.1B
Q1 25
$881.6M
$1.1B
Q4 24
$1.1B
Q3 24
$1.1B
Q2 24
$1.1B
Q1 24
$849.3M
$1.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBIO
BBIO
SCVL
SCVL
Operating Cash FlowLast quarter
$-56.4M
$33.6M
Free Cash FlowOCF − Capex
$-56.5M
$19.7M
FCF MarginFCF / Revenue
-36.6%
6.6%
Capex IntensityCapex / Revenue
0.0%
4.7%
Cash ConversionOCF / Net Profit
2.30×
TTM Free Cash FlowTrailing 4 quarters
$35.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBIO
BBIO
SCVL
SCVL
Q4 25
$-56.4M
$33.6M
Q3 25
$-109.6M
$13.3M
Q2 25
$-80.7M
$-9.6M
Q1 25
$-199.2M
$44.5M
Q4 24
$17.3M
Q3 24
$23.7M
Q2 24
$17.1M
Q1 24
$-219.5M
$53.4M
Free Cash Flow
BBIO
BBIO
SCVL
SCVL
Q4 25
$-56.5M
$19.7M
Q3 25
$-110.0M
$2.2M
Q2 25
$-81.3M
$-23.0M
Q1 25
$36.2M
Q4 24
$8.3M
Q3 24
$18.2M
Q2 24
$6.9M
Q1 24
$-220.2M
$40.7M
FCF Margin
BBIO
BBIO
SCVL
SCVL
Q4 25
-36.6%
6.6%
Q3 25
-91.2%
0.7%
Q2 25
-73.5%
-8.3%
Q1 25
13.8%
Q4 24
2.7%
Q3 24
5.5%
Q2 24
2.3%
Q1 24
-104.3%
14.5%
Capex Intensity
BBIO
BBIO
SCVL
SCVL
Q4 25
0.0%
4.7%
Q3 25
0.4%
3.6%
Q2 25
0.5%
4.8%
Q1 25
0.0%
3.2%
Q4 24
3.0%
Q3 24
1.7%
Q2 24
3.4%
Q1 24
0.3%
4.5%
Cash Conversion
BBIO
BBIO
SCVL
SCVL
Q4 25
2.30×
Q3 25
0.69×
Q2 25
-1.03×
Q1 25
3.04×
Q4 24
0.90×
Q3 24
1.05×
Q2 24
0.99×
Q1 24
3.44×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons